Index. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.

Transcription

1 Note: Page numbers of article titles are in boldface type. A Ablation therapy, for atrial fibrillation, 321 N-Acetyl-b-D-glucosaminidase, as biomarker, , 384, 387 N-Acetylcysteine, for CIN prevention, , 433 ACT (Acetylcysteine for Contrast Nephropathy) trial, 410, 414, 433 ACTIVE trial, 352 Acute coronary syndrome, diagnosis of, 319 Acute kidney injury. See Contrast-induced acute kidney injury. Acute Kidney Injury Network, 450 Acute Kidney Injury Network criteria, for prediction complications, A-HEFT study, 325 Airway compromise, in contrast media hypersensitivity, Allergic-like (anaphylactoid) reactions, to contrast media, Alpha GST, as biomarker, American College of Cardiology Foundation/Society for Cardiovascular Angiography and Interventions guidelines, for CIN prevention, , 433 Amiodarone, for atrial fibrillation, 321 Anaphylactoid reactions, to contrast media, Anemia, in heart failure, 324 Angioedema, in contrast media hypersensitivity, 343 Angiotensin, in CI-AKI, 365 Angiotensin receptor blockers, for heart failure, 323 Angiotensin-converting enzyme inhibitors, nephrotoxicity of, , Anticoagulation, for atrial fibrillation, 322 Antihypertensive drugs, for coronary artery disease, 320 Antioxidant mechanisms, fluid administration effects on, 395 Antiplatelet agents, for coronary artery disease, Aortic interventions, renal complications in, Aortic valve replacement, transcatheter, renal complications in, Apixaban, for atrial fibrillation, 322 Apoptosis, in CI-AKI, 364 ARMYDA-CIN (Atorvastatin for Reduction of Myocardial Damage during Angioplasty-contrast- Induced Nephropathy) trial, 409 Arrhythmias, from contrast media, 341 Ascorbic acid, for CIN prevention, Intervent Cardiol Clin 3 (2014) /14/$ see front matter Ó 2014 Elsevier Inc. All rights reserved. Aspiration system, for contrast media removal, Aspirin, for coronary artery disease, Atheroembolization, of renal artery, 445 Atherosclerosis coronary, peripheral, 451 Atorvastatin, for CI-AKI prevention, , 409 Atorvastatin for Reduction of Myocardial Damage during Angioplasty-contrast-Induced Nephropathy (ARMYDA-CIN) trial, 409 Atrial fibrillation, chronic kidney disease with, Atropine, for contrast media hypersensitivity, Attallah trial, of CI-AKI prevention, 407 Automated balanced hydration, 423, 425 AVERT contrast injection device, 422 B Bader trial, of fluid administration methods, Balloon(s), for contrast media removal, Bartholomew risk score, 371, 373 Benephit catheter, 426 Beta blockers for atrial fibrillation, 321 for contrast media hypersensitivity, 344 for coronary artery disease, 320 for heart failure, Bicarbonate, 397, 402, , Bicarbonate or Saline Study (BOSS), 402 Biomarkers, for CI-AKI and CIN, , clinical relevance of, clinical studies of, examples of, history of, ideal qualities of, 379 BioPorto assay, for neutrophil gelatinase-associated lipocalin, Bisoprolol, for atrial fibrillation, 321 Bleeding, in TAVR, 451 Blood transfusions, in TAVR, 451 Blue Cross Blue Shield of Michigan Cardiovascular Consortium registry, 432 BMC1 risk model, BOSS (Bicarbonate or Saline Study), 402 Bouzas-Mosquera trial, of CI-AKI prevention, 407 interventional.theclinics.com

2 456 Bradycardia, in contrast media hypersensitivity, 344 Bronchospasm, in contrast media hypersensitivity, Brown risk score, C CAPRICORN study, 325 Carbon dioxide angiography, 444 Cardiac Angiography In Renally Impaired Patients (CARE) trial, 353, 359 Cardiac magnetic resonance, for TAVR, 452 Cardiac resynchronization therapy, for heart failure, Cardiorenal syndrome, CARE (Cardiac Angiography In Renally Impaired Patients) trial, 353, 359 CARE-HF trial, 322, CHARM trial, 322, 325 Chemotoxicity, of contrast media, 341 Chen risk score, 375 Chen trial, of fluid administration methods, 396, 398 Chlorperazine, for contrast media hypersensitivity, Cho trial, of fluid administration methods, 398 Chronic Renal Insufficiency Cohort, 321 CI-AKI. See Contrast-induced acute kidney injury. CIBIS-II trial, 322, 325 CIN. See Contrast media-induced nephropathy. CINCOR removal system, 425 Clinical Outcomes Utilizing Revascularization and Aggressive Drug Treatment (COURAGE), 320 Computed tomography, pigtail, for TAVR, CONSENSUS study, 323, 325 Continuous veno-veno hemofiltration, for contrast media removal, Contrast media, angiography history and, 335 chemical properties of, classification of, dose of as CIN risk factor, 370 device control of, 422 for peripheral artery interventions, 443 high-osmolar, history of, 334 hydration before administering, iodine-based, ionic, low-osmolar, , maximum dose of, 370 nonionic, nonrenal complications of, anaphylactoid reactions, chemotoxic, 341 prevention of, risk factors for, 346 reflux of, control of, 422 removal devices for, safety profile of, types of, viscosity of, 338 volume of, control of, 422, 432, 444 Contrast media-induced nephropathy. See also Contrast-induced acute kidney injury. biomarkers for, clinical course of, 443 clinical manifestations of, 430 clinical studies of, contrast media factors in, definition of, 349, diagnosis of, 443 impact of, 442 in peripheral artery interventions, in TAVR, incidence of, mechanisms of, 430 osmolality in, pathogenesis of, pathophysiology of, 394, 442 prediction of, prevention of algorithm for, devices for, hydration before, pharmacologic methods for, practical approach to, strategies for, timing of, 434 relative toxicity of, risk factors for, , , Contrast-induced acute kidney injury, adverse events in, 359 biomarkers for, clinical manifestations of, 430 contrast media factors in, definition of, , epidemiology of, in peripheral artery interventions, in TAVR, mechanisms of, 430 pathophysiology of, prediction of, , prevention of, algorithm for, pharmacologic, , 433 practical approach to, strategies for, timing of, 434 risk factors for, , risk prediction for, staging of, 358 subclinical acute kidney injury in, Cooling, of kidney,

3 457 COPERNICUS study, 325 Coronary artery bypass surgery, for coronary artery disease, Coronary artery disease, chronic kidney disease with, diagnostic difficulties in, 319 interventions for, medical management of, Coronary sinus, contrast media removal from, Corticosteroids, for contrast media hypersensitivity, COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Treatment), 320 Creatinine as biomarker, 380, in CIN, Cystatin C, as biomarker, , automated balanced, 423, 425 CIN pathophysiology and, 394 clinical trials of, fluid tonicity and, 397, 400 fluid versus no fluid, 396, 398 for peripheral artery interventions, forced diuresis in, 397, history of, 396 oral versus intravenous, 396, rationale for, sodium chloride versus sodium bicarbonate in, 397, 402 suggestions for, 432 terminology of, timing of, Framingham Heart Study, atrial fibrillation risks and, 321 Freeman risk score, Fuji trial, of contrast media removal, 424 D Dabigatran, for atrial fibrillation, 322 Danenberg trial, for contrast media removal, 423, 425 Devices for CIN prevention, for heart failure, Diabetes mellitus, as CIN risk factor, 370 Diatrizoate, 351 DIG study, 325 Digoxin, for atrial fibrillation, 321 Diltiazem, for atrial fibrillation, 321 Diphenhydramine, for contrast media hypersensitivity, 344, 347 Diuresis, for CIN prevention, 425 Donedarone, for atrial fibrillation, 321 Duffy trial, for contrast media removal, 423, 425 Dussol trial, of fluid administration methods, 396, 398 E Echocardiography, for TAVR, 452 EMPHASIS-HF study, Endothelin, in CI-AKI, 365 Endovascular aortic repair, Enzyme-linked immunosorbent assay, for neutrophil gelatinase-associated lipocalin, Epinephrine, for contrast media hypersensitivity, EuroSCORE, for cardiac surgery, 451 F Fenoldopam, for CIN prevention, 426 Flecainide, for atrial fibrillation, 321 Fluid administration, , 434 G Glomerular filtration rate, as biomarker, 359, 380, 385 Glutathione 5-transferase, as biomarker, Gu trial, of fluid administration methods, 401 GuideLiner catheter, 432 Gurm model, for CIN prevention, 434 Gurm risk score, 371, 375 Gurm trial, for CIN prevention, 422 H Han trial, of CI-AKI prevention, Heart failure, device therapy for, in CI-AKI, medical management of, Hemodialysis, for contrast media removal, , 434 Hemodynamic effects, in CI-AKI, Hemodynamic instability, as CIN risk factor, Hepcidin, as biomarker, 385 Hexabrix, High-osmolar contrast media, HOT (Hypertension Optimal Treatment) study, Hua trial, of CI-AKI prevention, 408 Hydration. See Fluid administration. Hypertension, treatment of, 320 Hypertension Optimal Treatment (HOT) study, Hypotension from contrast media, 341 in TAVR, 452 Hypothermia, for CIN prevention, 426 Hypoxia, in CI-AKI,

4 458 I Idiosyncratic (anaphylactoid) reactions, to contrast media, Immunochromatographic assay, for kidney injury molecule, IMPACT trial, 353 Implantable cardioverter-defibrillator, for heart failure, Insulin-like growth factor-binding protein 7, as biomarker, , 384 Interleukin-18, as biomarker, , 383, Intrarenal drug infusion, 426 Iodine-based contrast media, chemical properties of, Iodixanol, 338 for peripheral artery interventions, 443 nephrotoxicity of, properties of, 351 Iohexol, 337, 351, Iopamidol, 337, 351, 354 Iopramidol, 337 Iopromide, 337, 351, 354 Ioversol, 337, 351, 354 Ioxaglate, 351, Ischemic conditioning, remote, 426 J Jo trial, of CI-AKI prevention, 408 K Kandula trial, of CI-AKI prevention, 407 Khanal trial, of CI-AKI prevention, 406 Kidney disease and injury contrast-induced. See also Contrast mediainduced nephropathy; Contrast-induced acute kidney injury. device-mediated protective devices for, implications of, classification, 317 with atrial fibrillation, with coronary artery disease, with heart failure, in TAVR, infarction, 445 prevention of, Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for Acute Kidney Injury, 353, 355, Kidney injury molecule, as biomarker, , Kong trial, of fluid administration methods, 399 Krasuski trial, of fluid administration methods, 397, 400 L Lawlor trial, of fluid administration methods, 399 Lehnert trial, for contrast media removal, Leoncini trial, of CI-AKI prevention, Li trial, of CI-AKI prevention, Lin trial, of CI-AKI prevention, 408 Liver-type fatty acid binding protein, as biomarker, , 384, 387 Logistic EuroSCORE, for cardiac surgery, 451 Low-osmolar contrast media, chemical structures of, 350 nephropathy induced by, L-type fatty acid binding protein, as biomarker, , 384, 387 M McCullough risk score, MADIT study, 325 Maioli risk score, 374 Maioli trial, of fluid administration methods, 396, 398 Majumdar trial, of fluid administration methods, 401 Marenzi risk score, 373, 376 Marenzi trial, for contrast media removal, Marron trial, of fluid administration methods, 397, 400 Maximal acceptable contrast dose, Maximum contrast dose, 370 Mehran model, for CIN prevention, 434 Mehran risk score, 371, 373, 376, 430 MERIT-HF study, 325 Merten trial, for CIN prevention, 433 Methylprednisolone, for contrast media hypersensitivity, 347 Metrizamide, 337 Metrizoate, properties of, 351 Meyer trial, of contrast media removal, 424 Michishita trial, of contrast media removal, 424 Midkine, as biomarker, Mineralocorticoid receptor antagonists, for heart failure, MIRACLE study, Mortality in CI-AKI, 360 in TAVR, 451 Movahed trial, of contrast media removal, 424 Mueller trial, of fluid administration methods, 397, 400 Myocardial infarction, in CI-AKI, Myocardial ischemia, from contrast media, 341 MYTHOS trial, 425, 432 N Nayak trial, for CIN prevention, 436 NEPHRIC trial, 353 NephroCheck test, 361

5 459 Nephropathy induced by low-osmolar contrast media, Neutrophil gelatinase-associated lipocalin, as biomarker, , , 386 NGAL Test, 385 NSAIDs, nephrotoxicity of, 433 O Ondansetron, for contrast media hypersensitivity, Osmotic nephrosis, Oxygen consumption, fluid administration effects on, 395 Oxygen free radicals, in CI-AKI, 364 Oxygen therapy, for contrast media hypersensitivity, 344 Ozhan trial, of CI-AKI prevention, 408 P PARTNER trial, 450 Patti trial, of CI-AKI prevention, 406, Percutaneous coronary intervention, for coronary artery disease, 320 Peripheral artery interventions, renal complications in, CIN, in aortic interventions, in renal artery interventions, Pigtail computed tomography, for TAVR, POSEIDON trial, 435 PRATO-ACS (Protective effect of Rosuvastatin and Antiplatelet Therapy on contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome) trial, , 433 Pravastatin, for CI-AKI prevention, 407 PREDICT trial, 353 Prediction rules, for renal complications, Prednisone, for contrast media hypersensitivity, 347 PRESERVE (Prevention of Serious Adverse Events following Angiography) trial, 414 PRINCE trial, 425 Prochlorperazine, for contrast media hypersensitivity, 344 Protective effect of Rosuvastatin and Antiplatelet Therapy on contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome (PRATO-ACS) trial, , 433 Proteinuria, as biomarker, 380 Pseudoallergic (anaphylactoid) reactions, to contrast media, Q Quintavalle trial, of CI-AKI prevention, R RALES study, 325 Rash, in contrast media hypersensitivity, 343, RECOVER trial, 353 REGARDS study, 321 REMEDIAL trial, 433 Remote ischemic conditioning, 426 Renal artery interventions, renal complications in, Renal Insufficiency Trial After Contrast Media Administration, 425 RenalGuard system, 425 Renin-angiotensin-aldosterone system, fluid administration effects on, 395 RENO study, 433 Reverse Berman catheter, 425 REVERSE study, 325 RIFLE classification, of acute kidney injury, 450 Rivaroxaban, for atrial fibrillation, 322 Rosuvastatin, for CI-AKI prevention, S Sadat trial, for CIN prevention, 425 Saline solution, for volume expansion, Seizures, in contrast media hypersensitivity, 343 SHARP (Study of Heart and Renal Protection), 320 SHIFT study, 325 Simvastatin, for CI-AKI prevention, Skin disorders, in contrast media hypersensitivity, 343, Skin test, for contrast media reactions, 343, 346 Sodium bicarbonate, 397, 402, Solomon trial, of fluid administration methods, 401 SOLVD trial, 322, 325 Sotolol, for atrial fibrillation, 321 Statins for CIN prevention, , 433 for coronary artery disease, 320 Stents, for renal artery stenosis, Stevens trial, of fluid administration methods, 402 Stroke, in CI-AKI, Study of Heart and Renal Protection (SHARP), 320 SWEDEHEART register, 319 Sympathetic nervous system, fluid administration effects on, 395 T TAVR (transcatheter aortic valve replacement), renal complications in, Taylor trial, of fluid administration methods, Tepel trial, for CIN prevention, Tissue inhibitor of metalloproteinases, as biomarker, Topo trial, of CI-AKI prevention, 408

6 460 Transcatheter aortic valve replacement, renal complications in, Trivedi trial, of fluid administration methods, 398 Tubular cell toxicity, in CI-AKI, Tziakas risk score, 371, 374 U Ultrasonography, for assessing lesion size, 432, 444 Urine biomarkers in, , characteristics of, fluid administration effects on, Urticaria, in contrast media hypersensitivity, V VALOR trial, 353 Valve Academic Research Consortium, 450 Vasa recta, contrast media effects on, 366 Vasoactive mediators, in CI-AKI, Vasoconstrictive factors, fluid administration effects on, 395 Vasopressin fluid administration effects on, 395 in CI-AKI, 365 Vasovagal reactions, versus contrast media hypersensitivity, 343 Vogt trial, for contrast media removal, W Warfarin, for atrial fibrillation, 322 Weinstein trial, of fluid administration methods, 400 Western blot test, for neutrophil gelatinaseassociated lipocalin, 384 Wrobel trial, of fluid administration methods, 399 X Xinwei trial, of CI-AKI prevention, 408 X-rays, discovery of, 334 Y Yoshida trial, of CI-AKI prevention, 407 Yoshikawa trial, of fluid administration methods, 396 Z Zhao trial, of CI-AKI prevention, 407 Zhou trial, of CI-AKI prevention, 408